LP(a)-LOWERING THERAPIES (siRNA / ASO) AND ATHEROSCLEROTIC RISK REDUCTION

Background: Genetically determined and independent risk factor, High levels of lipoprotein(a) [Lp(a)].Traditional lipid-lowering drugs like statins and PCSK9 inhibitors are not effective enough to decrease the levels of Lp(a) and leave a considerable amount of cardiovascular risk.New RNA-based treatment approaches, such as small interfering RNA (siRNA) and antisense oligonucleotides (ASOs), are currently appearing as the potential solutions, which can significantly reduce the levels of Lp(a) by acting on the expression of the hepatic LPA gene.The purpose of this study was to assess the professional attitudes to the safety, efficacy, and clinical relevance of Lp (a)-lowering RNA therapeutics and their role in reducing the risk of ASCVD.Methods: A cross-sectional survey was carried out quantitatively on cardiology, pharmacology, and molecular biology professionals.A 30-item Likert-scale questionnaire (1 = Strongly Disagree to 5 = Strongly Agree) was designed to gather the data and was given to 263 respondents.The data were analyzed through SPSS 26 in terms of Normality (Shapiro-Wilk), Reliability (Cronbach-alpha), and Validity (KMO and Bartlett's), Inferential Tests (t-test, ANOVA, Kruskal-Wallis, Chi-square).Pearson correlation and multiple regression analysis were also done to test associations and predictive relationships between variables. Results:The distribution of all items was found to be normal (p > 0.05) and had a high reliability (0.978) and a high construct validity (KMO = 0.874, p = 0.001).There were also notable variations by gender, age, and education level (p < 0.05), and this demonstrates that demographic and professional variables have a role in perceptions of RNA-based lipid-lowering therapy.Correlation analysis showed that there were strong positive relationships between all variables (r = 0.680.88,p < 0.01).The significance of the regression model was (R 2 = 0.716, p = 0.001), which indicated that awareness, perceived efficacy, safety, and adoption intention had positive influences on attitudes toward risk reduction of ASCVD.Conclusion: The research supports the hypothesis that healthcare and biomedical professionals have a very favorable opinion of Lp(a)-lowering siRNA/ASO therapies as a safe and effective method of residual cardiovascular risk management.The statistical results indicate a high level of reliability, validity, and predictability, which attests to the high level of professional trust in RNA-based therapeutics.Such results justify the importance of genetic and molecular treatments in the future cardiovascular risk management systems, which would be a significant change towards precision lipidology and personalized medicine.